カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

非定型奇形性ラブドイド腫瘍（ATRT）治療のグローバル市場2023：手術、化学療法、放射線療法、標的免疫療法

■ 英語タイトル：Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR23AG9516）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR23AG9516
■ 発行日：2023年8月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：92
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥501,120見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥751,680見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,002,240見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[非定型奇形性ラブドイド腫瘍（ATRT）治療のグローバル市場2023：手術、化学療法、放射線療法、標的免疫療法]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Global Info Research社の最新の調査によると、非定型奇形性ラブドイド腫瘍（ATRT）治療のグローバル市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
本調査レポートは、世界の非定型奇形性ラブドイド腫瘍（ATRT）治療市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本資料の主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- 非定型奇形性ラブドイド腫瘍（ATRT）治療の成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

非定型奇形性ラブドイド腫瘍（ATRT）治療市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメント
・手術、化学療法、放射線療法、標的免疫療法

用途別セグメント
・診療所、病院、その他

主要な市場プレーヤー
・Takeda Pharmaceutical Company、Vyriad Inc、Novartis Oncology、Istari Oncology Inc.、Secura Bio, Inc.、Pfizer, Inc.、Ipsen Pharma、Exelixis, Inc.

地域別セグメントは次の地域・国をカバーします。
・北米（アメリカ、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、非定型奇形性ラブドイド腫瘍（ATRT）治療製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な非定型奇形性ラブドイド腫瘍（ATRT）治療メーカーの企業概要、2019年～2022年までの非定型奇形性ラブドイド腫瘍（ATRT）治療の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な非定型奇形性ラブドイド腫瘍（ATRT）治療メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別非定型奇形性ラブドイド腫瘍（ATRT）治療の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの非定型奇形性ラブドイド腫瘍（ATRT）治療の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での非定型奇形性ラブドイド腫瘍（ATRT）治療市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および非定型奇形性ラブドイド腫瘍（ATRT）治療の産業チェーンを掲載しています。
・第14、15章では、非定型奇形性ラブドイド腫瘍（ATRT）治療の販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– 非定型奇形性ラブドイド腫瘍（ATRT）治療の概要
– 種類別分析（2018年vs2022年vs2029年）：手術、化学療法、放射線療法、標的免疫療法
– 用途別分析（2018年vs2022年vs2029年）：診療所、病院、その他
– 世界の非定型奇形性ラブドイド腫瘍（ATRT）治療市場規模・予測
– 世界の非定型奇形性ラブドイド腫瘍（ATRT）治療生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Takeda Pharmaceutical Company、Vyriad Inc、Novartis Oncology、Istari Oncology Inc.、Secura Bio, Inc.、Pfizer, Inc.、Ipsen Pharma、Exelixis, Inc.
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年：手術、化学療法、放射線療法、標的免疫療法
・用途別分析2018年-2029年：診療所、病院、その他
・非定型奇形性ラブドイド腫瘍（ATRT）治療の北米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・非定型奇形性ラブドイド腫瘍（ATRT）治療のヨーロッパ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・非定型奇形性ラブドイド腫瘍（ATRT）治療のアジア市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・非定型奇形性ラブドイド腫瘍（ATRT）治療の南米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・非定型奇形性ラブドイド腫瘍（ATRT）治療の中東・アフリカ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Product Overview and Scope of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Surgery
1.3.3 Chemotherapy
1.3.4 Radiation
1.3.5 Targeted Immunotherapy
1.4 Market Analysis by Application
1.4.1 Overview: Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Clinic
1.4.3 Hospital
1.4.4 Others
1.5 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size & Forecast
1.5.1 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (2018-2029)
1.5.3 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Takeda Pharmaceutical Company
2.1.1 Takeda Pharmaceutical Company Details
2.1.2 Takeda Pharmaceutical Company Major Business
2.1.3 Takeda Pharmaceutical Company Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.1.4 Takeda Pharmaceutical Company Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Takeda Pharmaceutical Company Recent Developments/Updates
2.2 Vyriad Inc
2.2.1 Vyriad Inc Details
2.2.2 Vyriad Inc Major Business
2.2.3 Vyriad Inc Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.2.4 Vyriad Inc Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Vyriad Inc Recent Developments/Updates
2.3 Novartis Oncology
2.3.1 Novartis Oncology Details
2.3.2 Novartis Oncology Major Business
2.3.3 Novartis Oncology Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.3.4 Novartis Oncology Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Novartis Oncology Recent Developments/Updates
2.4 Istari Oncology Inc.
2.4.1 Istari Oncology Inc. Details
2.4.2 Istari Oncology Inc. Major Business
2.4.3 Istari Oncology Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.4.4 Istari Oncology Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Istari Oncology Inc. Recent Developments/Updates
2.5 Secura Bio, Inc.
2.5.1 Secura Bio, Inc. Details
2.5.2 Secura Bio, Inc. Major Business
2.5.3 Secura Bio, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.5.4 Secura Bio, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Secura Bio, Inc. Recent Developments/Updates
2.6 Pfizer, Inc.
2.6.1 Pfizer, Inc. Details
2.6.2 Pfizer, Inc. Major Business
2.6.3 Pfizer, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.6.4 Pfizer, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Pfizer, Inc. Recent Developments/Updates
2.7 Ipsen Pharma
2.7.1 Ipsen Pharma Details
2.7.2 Ipsen Pharma Major Business
2.7.3 Ipsen Pharma Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.7.4 Ipsen Pharma Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Ipsen Pharma Recent Developments/Updates
2.8 Exelixis, Inc.
2.8.1 Exelixis, Inc. Details
2.8.2 Exelixis, Inc. Major Business
2.8.3 Exelixis, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
2.8.4 Exelixis, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Exelixis, Inc. Recent Developments/Updates
3 Competitive Environment: Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment by Manufacturer
3.1 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Manufacturer (2018-2023)
3.2 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Revenue by Manufacturer (2018-2023)
3.3 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Manufacturer Market Share in 2022
3.4.2 Top 6 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Manufacturer Market Share in 2022
3.5 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market: Overall Company Footprint Analysis
3.5.1 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market: Region Footprint
3.5.2 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market: Company Product Type Footprint
3.5.3 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size by Region
4.1.1 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2018-2029)
4.1.2 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2018-2029)
4.1.3 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Region (2018-2029)
4.2 North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029)
4.3 Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029)
4.4 Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029)
4.5 South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029)
4.6 Middle East and Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2029)
5.2 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Type (2018-2029)
5.3 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2029)
6.2 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Application (2018-2029)
6.3 Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Application (2018-2029)
7 North America
7.1 North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2029)
7.2 North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2029)
7.3 North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size by Country
7.3.1 North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2018-2029)
7.3.2 North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2029)
8.2 Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2029)
8.3 Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size by Country
8.3.1 Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2018-2029)
8.3.2 Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size by Region
9.3.1 Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2029)
10.2 South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2029)
10.3 South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size by Country
10.3.1 South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2018-2029)
10.3.2 South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Size by Country
11.3.1 Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Drivers
12.2 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Restraints
12.3 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment and Key Manufacturers
13.2 Manufacturing Costs Percentage of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment
13.3 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Production Process
13.4 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Typical Distributors
14.3 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Takeda Pharmaceutical Company Basic Information, Manufacturing Base and Competitors
Table 4. Takeda Pharmaceutical Company Major Business
Table 5. Takeda Pharmaceutical Company Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 6. Takeda Pharmaceutical Company Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Takeda Pharmaceutical Company Recent Developments/Updates
Table 8. Vyriad Inc Basic Information, Manufacturing Base and Competitors
Table 9. Vyriad Inc Major Business
Table 10. Vyriad Inc Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 11. Vyriad Inc Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Vyriad Inc Recent Developments/Updates
Table 13. Novartis Oncology Basic Information, Manufacturing Base and Competitors
Table 14. Novartis Oncology Major Business
Table 15. Novartis Oncology Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 16. Novartis Oncology Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Novartis Oncology Recent Developments/Updates
Table 18. Istari Oncology Inc. Basic Information, Manufacturing Base and Competitors
Table 19. Istari Oncology Inc. Major Business
Table 20. Istari Oncology Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 21. Istari Oncology Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Istari Oncology Inc. Recent Developments/Updates
Table 23. Secura Bio, Inc. Basic Information, Manufacturing Base and Competitors
Table 24. Secura Bio, Inc. Major Business
Table 25. Secura Bio, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 26. Secura Bio, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Secura Bio, Inc. Recent Developments/Updates
Table 28. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 29. Pfizer, Inc. Major Business
Table 30. Pfizer, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 31. Pfizer, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Pfizer, Inc. Recent Developments/Updates
Table 33. Ipsen Pharma Basic Information, Manufacturing Base and Competitors
Table 34. Ipsen Pharma Major Business
Table 35. Ipsen Pharma Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 36. Ipsen Pharma Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Ipsen Pharma Recent Developments/Updates
Table 38. Exelixis, Inc. Basic Information, Manufacturing Base and Competitors
Table 39. Exelixis, Inc. Major Business
Table 40. Exelixis, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Product and Services
Table 41. Exelixis, Inc. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Exelixis, Inc. Recent Developments/Updates
Table 43. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 44. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Revenue by Manufacturer (2018-2023) & (USD Million)
Table 45. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 46. Market Position of Manufacturers in Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 47. Head Office and Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Production Site of Key Manufacturer
Table 48. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market: Company Product Type Footprint
Table 49. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market: Company Product Application Footprint
Table 50. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment New Market Entrants and Barriers to Market Entry
Table 51. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 52. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 53. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 54. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 55. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 56. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Region (2018-2023) & (US$/Unit)
Table 57. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Region (2024-2029) & (US$/Unit)
Table 58. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 59. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 60. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 61. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 62. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Type (2018-2023) & (US$/Unit)
Table 63. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Type (2024-2029) & (US$/Unit)
Table 64. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 65. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 66. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 67. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 68. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Application (2018-2023) & (US$/Unit)
Table 69. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Application (2024-2029) & (US$/Unit)
Table 70. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 71. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 72. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 73. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 74. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 75. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 76. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 77. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 78. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 79. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 80. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 81. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 82. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 83. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 84. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 85. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 86. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 87. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 88. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 89. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 90. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 91. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 92. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 93. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 94. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 95. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 96. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 97. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 98. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 99. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 100. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 101. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 102. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 103. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 104. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 105. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 106. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 107. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 108. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 109. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 110. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Raw Material
Table 111. Key Manufacturers of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Raw Materials
Table 112. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Typical Distributors
Table 113. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Typical Customers
List of Figures
Figure 1. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Picture
Figure 2. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Type in 2022
Figure 4. Surgery Examples
Figure 5. Chemotherapy Examples
Figure 6. Radiation Examples
Figure 7. Targeted Immunotherapy Examples
Figure 8. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Application in 2022
Figure 10. Clinic Examples
Figure 11. Hospital Examples
Figure 12. Others Examples
Figure 13. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 55. China Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Drivers
Figure 76. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Restraints
Figure 77. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment in 2022
Figure 80. Manufacturing Process Analysis of Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment
Figure 81. Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source

※参考情報

非定型奇形性ラブドイド腫瘍（Atypical Teratoid Rhabdoid Tumours, ATRT）は、特に小児において発生する悪性脳腫瘍の一種であり、その発生は主に脳幹や大脳半球、または脊髄に見られます。この腫瘍は、高い悪性度を持つため、治療が非常に困難であり、患者の予後は極めて不良です。

ATRTは、通常、幼児や小さな子供に多く見られ、特に18カ月から3歳の年齢層で最も頻繁に診断されます。この腫瘍の特徴としては、特定の遺伝子変異が関連していることが挙げられます。INK4A/ARF遺伝子の欠失やSMARCB1遺伝子の変異が、腫瘍の発生と進行に関与していることが知られています。これらの遺伝子の異常は、腫瘍細胞の増殖や生存に直接的な影響を及ぼします。

膀胱腫瘍、悪性神経芽腫、上皮性腫瘍など様々な腫瘍と比較した場合、ATRTはその組織学的特徴や遺伝子学的背景から独自の存在感を示します。腫瘍細胞は、しばしば成長が早く、局所浸潤性が強いため、周囲の脳組織に対しても強い影響を及ぼします。

ATRTの診断は、主に画像診断と組織学的検査によって行われます。MRIやCTスキャンなどの画像診断では、腫瘍の位置や大きさ、隣接する組織への侵入状況を確認することができます。一方、確定診断には腫瘍からの組織サンプルを採取し、顕微鏡で観察することが必要です。この際、腫瘍細胞の形態学的特性を解析し、特異的なバイオマーカーの存在を確認することが重要です。

ATRTの治療は多岐にわたり、一般的には手術、放射線療法、化学療法を組み合わせた集学的アプローチが採用されます。腫瘍が局所的に限定されている場合は、まず手術による腫瘍摘出が試みられます。しかし、腫瘍の広がりや周囲の重要な脳組織への浸潤状況によっては、手術が困難な場合もあります。

手術後は、残存腫瘍や転移のリスクを低減させるために、放射線療法と化学療法が併用されます。化学療法には、一般的にビンクリスチンやシスプラチン、ドキソルビシン等が使用されます。最近では、新しい薬剤や治療法も開発されており、特に分子標的治療や免疫療法が注目されています。これにより、従来の治療法に対する耐性を示す腫瘍に対しても新たな治療の選択肢を提供することが期待されています。

ATRTに関する近年の研究では、腫瘍の遺伝子プロファイリングを用いた個別化治療の可能性も模索されています。これにより、患者ごとの腫瘍の特性に基づいたより効果的な治療戦略の策定が進められています。また、治療の効果をモニタリングするための非侵襲的なバイオマーカーの開発も進行中であり、これにより治療効果の評価や早期の再発検出が可能となることが期待されています。

さらに、ATRTの治療において精神的な支援や外科的治療後のリハビリテーションも重要な要素です。治療過程での心理的ストレスや身体的な制約に対処するために、専門の医療スタッフによるサポートが必要です。また、家族へのカウンセリングや情報提供も重要視されています。

ATRTは、治療が難しく予後が不良な腫瘍であるため、医療現場では引き続き研究が進められています。新たなバイオマーカーの発見や治療法の開発に向けた取り組みが推進されており、将来的には予後の改善に寄与することが期待されています。患者とその家族にとって希望となる新しい治療法の開発は、ATRTに関する研究の最前線で進められています。このような試みが成功し、ATRTの患者に対する治療成績の向上が見られるようになれば、医療従事者や研究者にとっても大きな励みとなるでしょう。ATRTの治療に関する研究は、今後も重要な課題として位置付けられ、多くの関心が寄せられることでしょう。


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • カルチノイド腫瘍症候群の治療のグローバル市場2023：化学療法、生物学的療法、放射線療法
  • カルチノイド腫瘍症候群治療の世界市場2023-2029：化学療法、生物学的療法、放射線療法
  • 非黒色腫皮膚がん治療のグローバル市場：化学療法、放射線療法、光線力学的療法、その他
  • 上咽頭がんのグローバル市場（2022年-2029年）：化学療法、免疫療法、放射線療法、その他
  • 軟部腫瘍のグローバル市場（2023年-2030年）：標的療法、化学療法、血管新生阻害薬、放射線療法
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR23AG9516 )"非定型奇形性ラブドイド腫瘍（ATRT）治療のグローバル市場2023：手術、化学療法、放射線療法、標的免疫療法" (英文：Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。